Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa

• Published in: The Journal of infectious diseases Vol. 214; no. 6; pp. 873 - 883
• Main Authors: Boender, T. Sonia, Hamers, Raph L., Ondoa, Pascale, Wellington, Maureen, Chimbetete, Cleophas, Siwale, Margaret, Maksimos, Eman E. F. Labib, Belinda, Sheila N., Kityo, Cissy M., Adeyemo, Titilope A., Akanmu, Alani Sulaimon, Mandaliya, Kishor, Botes, Mariette E., Stevens, Wendy, de Wit, Tobias F. Rinke, Sigaloff, Kim E.
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 15.09.2016
• Subjects: Adolescent; Adult; Africa South of the Sahara - epidemiology; Anti-Retroviral Agents - therapeutic use; Drug Resistance, Viral; Female; HIV Infections - drug therapy; HIV Infections - epidemiology; HIV Infections - virology; HIV Protease Inhibitors - pharmacology; HIV-1 - drug effects; HIV-1 - isolation & purification; HIV/AIDS; Humans; Lentivirus; Male; Middle Aged; Mutation; Prevalence; Prospective Studies; Retroviridae; Young Adult; Africa; HIV-1; protease inhibitor; second-line antiretroviral therapy; sub-Saharan Africa; drug resistance

Background. As antiretroviral therapy (ART) programs in sub-Saharan Africa mature, increasing numbers of persons with human immunodeficiency virus (HIV) infection will experience treatment failure, and require second- or third-line ART. Data on second-line failure and development of protease inhibit...